drugset / Trial / NCT06306339
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of intravenous infusions of burfiralimab (hzVSF-v13) when added to Disease-Modifying Antirheumatic Drug (DMARD) treatment as Standard of Care (SOC) in participants with moderate to severe Rheumatoid Arthritis (RA).
Timeline
- Start
- 2024-03
- Primary completion
- 2025-05
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Burfiralimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Burfiralimab | Monoclonal antibody | 600 mg | Intravenous |